Lastly, Es has been tested has a tool to predict clinical outcomes in IPAH, and CHD and CTD-PAH, in addition to tools that are currently validated [REVEAL, ESC/ERS (221), and NT-proBNP (222)], and it was able to improve their performance in risk discrimination and mortality stratification. This evidence concerns the gene NPPB and pulmonary arterial hypertension.